Fahd Al Mulla

Summary

Affiliation: Faculty of Medicine
Country: Kuwait

Publications

  1. Ali H, Al Mulla F, Hussain N, Naim M, Asbeutah A, AlSahow A, et al. PKD1 Duplicated regions limit clinical Utility of Whole Exome Sequencing for Genetic Diagnosis of Autosomal Dominant Polycystic Kidney Disease. Sci Rep. 2019;9:4141 pubmed publisher
    ..Enhancing reading depth, quality and sensitivity of WES in the PKD1 duplicated regions (exons 1-32) is crucial for its potential diagnostic or research applications. ..
  2. request reprint
    Al Mulla F, MacKenzie E. Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol. 2001;195:549-56 pubmed
    ..The precise mechanisms behind these biological differences in vivo and in vitro should now be investigated. ..
  3. request reprint
    Al Mulla F, Abdulrahman M, Varadharaj G, Akhter N, Anim J. BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry. J Histochem Cytochem. 2005;53:621-9 pubmed
    ..Antibody 8F7 had the highest sensitivity of 100%, but its specificity was 30.4% if mRNA levels were considered as the reference standard. ..
  4. Ali R, Marafie M, Bitar M, Al Dousari F, Ismael S, Bin Haider H, et al. Gender-associated genomic differences in colorectal cancer: clinical insight from feminization of male cancer cells. Int J Mol Sci. 2014;15:17344-65 pubmed publisher
    ..In summary, our data show that some CNAs in CRC may be gender specific and that male cancers characterized by feminization may constitute a specific subset of CRCs that warrants further investigation. ..
  5. Ali H, Hussain N, Naim M, Zayed M, Al Mulla F, Kehinde E, et al. A novel PKD1 variant demonstrates a disease-modifying role in trans with a truncating PKD1 mutation in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2015;16:26 pubmed publisher
    ..Understanding the molecular mechanism through which the gene exerts its disease modifying role may aid our understanding of the pathogenesis of ADPKD. ..
  6. Jalkh N, Chouery E, Haidar Z, Khater C, Atallah D, Ali H, et al. Next-generation sequencing in familial breast cancer patients from Lebanon. BMC Med Genomics. 2017;10:8 pubmed publisher
    ..Importantly, the overall mutation prevalence was equal to 40%, justifying the urgent need to deploy WES for the identification of genetic variants responsible for familial BC in the Lebanese population. ..
  7. Al Mulla F, Bland J, Serratt D, Miller J, Chu C, Taylor G. Age-dependent penetrance of different germline mutations in the BRCA1 gene. J Clin Pathol. 2009;62:350-6 pubmed publisher
    ..The data have important ramifications on screening, genetic counselling and prophylactic treatment of BRCA1 gene mutation carriers. ..
  8. Al Temaimi R, Tan T, Marafie M, Thiery J, Quirke P, Al Mulla F. Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse. Int J Mol Sci. 2016;17: pubmed publisher
    ..The identified 42 genes may be useful for predicting metastatic relapse in stage II CRC. Further studies are necessary to validate these findings. ..
  9. Al Mulla F, Hagan S, Al Ali W, Jacob S, Behbehani A, Bitar M, et al. Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. J Clin Pathol. 2008;61:524-9 pubmed publisher
    ..RKIP loss by hypermethylation of its promoter could have a significant influence on colorectal cancer aneuploidy, which might explain its association with metastatic progression. ..

More Information

Publications14

  1. Al Mulla F, Bitar M, Taqi Z, Rath O, Kolch W. RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Mol Biosyst. 2011;7:928-41 pubmed publisher
  2. Al Mulla F, Bitar M, Taqi Z, Yeung K. RKIP: much more than Raf kinase inhibitory protein. J Cell Physiol. 2013;228:1688-702 pubmed publisher
    ..Specific biological and functional niches are highlighted to focus future research towards an enhanced understanding of the multiple roles of RKIP in health and disease. ..
  3. Al Mulla F, Bitar M, Al Maghrebi M, Behbehani A, Al Ali W, Rath O, et al. Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3?. Cancer Res. 2011;71:1334-43 pubmed publisher
    ..RKIP levels in human colorectal cancer positively correlate with GSK3? expression. These findings reveal the RKIP/GSK3 axis as both a potential therapeutic target and a prognosis-based predictor of cancer progression. ..
  4. Al Mulla F, Leibovich S, Francis I, Bitar M. Impaired TGF-? signaling and a defect in resolution of inflammation contribute to delayed wound healing in a female rat model of type 2 diabetes. Mol Biosyst. 2011;7:3006-20 pubmed publisher
  5. Al Mulla F, Bitar M, Feng J, Park S, Yeung K. A new model for raf kinase inhibitory protein induced chemotherapeutic resistance. PLoS ONE. 2012;7:e29532 pubmed publisher
    ..Our data illuminate, for the first time, the NRF2-KEAP 1 pathway as a possible target for personalized therapeutic intervention in RKIP depleted cancers. ..